Transaction #26670 · Form 4 · 0001193125-26-001172
Xenon Pharmaceuticals Inc. · Exercise / conversion · Common Shares
Xenon Pharmaceuticals Inc. · Transacted January 2, 2026 · Filed January 2, 2026
What does this filing report?
An SEC Form 4 filing for Xenon Pharmaceuticals Inc. records an exercise / conversion involving Common Shares on January 2, 2026. The reported quantity was 40,000. The filing date is January 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Xenon Pharmaceuticals Inc.
- Company CIK
- 0001582313
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 40,000
- Reported price
- 7.49
- Reference value
- 299,600
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 46,000
- Ownership description
- Not reported
- SEC acceptance time
- Jan 2, 2026, 6:49 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- MORTIMER IAN ↗
PRESIDENT & CEO · Director
CIK 0001619961
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 27, 2024.
- F2
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F3
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- F4
- The shares subject to the option are fully vested and exercisable.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.